Xeris Biopharma
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, n...
Latest News
4 days ago · seekingalpha.com
Xeris Biopharma: Time For A PauseXeris Biopharma Holdings has more than doubled since my March buy rating, driven by strong Q3 results and raised guidance. XERS posted a surprise GAAP profit of $0.06 per share, $11.3M net income, and 44% revenue growth to $107.2M, exceeding expectations. Gross margins improved to 88%, and Xeris eliminated $34M of convertible notes, reducing annual interest by $3M and strengthening its balance sheet.
10 days ago · marketbeat.com
Xeris Biopharma Q3 Earnings Call HighlightsXeris Biopharma NASDAQ: XERS raised its 2026 revenue guidance and its 2030 outlook after third-quarter sales increased 44% year over year, driven by rapid growth in its Cushing syndrome treatment Recorlev.
11 days ago · seekingalpha.com
Xeris Biopharma Holdings, Inc. (XERS) Q3 2026 Earnings Call TranscriptXeris Biopharma Holdings, Inc. ( XERS ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Cristi Barnett - Vice President of Investor Relations John Shannon - Chairman & CEO Steven Pieper - Chief Financial Officer Conference Call Participants Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Hello, everyone.
12 days ago · zacks.com
Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesAlthough the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
24 days ago · gurufocus.com
Xeris Biopharma Holdings Inc (XERS) Stock Down 6.1% but Still Overvalued -- GF Score: 66/100On October 23, 2026, Xeris Biopharma Holdings Inc (XERS) shares fell 6.1% to a current price of $10.20, within a 52-week range of $5.25 to $11.42. This price mo
26 days ago · businesswire.com
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced it will release its financial results and business highlights for the third quarter ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 5, 2026. Management will host a conference call.
2 months ago · reuters.com
Lundbeck expresses interest in buying Xeris, Bloomberg News reportsDanish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma , Bloomberg News reported on Tuesday, citing people familiar with the matter.
2 months ago · seekingalpha.com
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy TranscriptXeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript
3 months ago · businesswire.com
Xeris Announces Details for XP-8121 Program Overview WebinarCHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company's Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism. The XP-8121 webinar will take place on Wednesday, Septemb.
3 months ago · seekingalpha.com
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy OpportunityXeris Biopharma Holdings, Inc. achieved record 2024 revenues of $203M, up 24%, with robust growth across all three commercial products. 2025 revenue guidance of $255M–$275M implies 30% growth for XERS at midpoint, supporting a forward P/S ratio of ~3.4x and fair valuation. XP-8121, a once-weekly injectable levothyroxine, targets a $1B+ U.S. market and could be a future blockbuster pending Phase 3 trial initiation.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove XERS